Because we’re here to serve our team

Depth of knowledge and diversity of experience are what allow our executive leadership to mentor, motivate and maintain our vision. Our other key leaders round out our expertise in mission critical specialties. Our board of directors also draws upon decades of leadership to help define our way forward.

Our Executive Leadership

Brian Markison

Chief Executive Officer

Brian Markison joined the Lantheus Board in September 2012 and served as Chairperson from January 2013 until March 2024, when he became the Chief Executive Officer. Mr. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. Mr. Markison has been a Healthcare Industry Executive for Avista Capital Partners since September 2012. He is currently a Director of RVL Pharmaceuticals plc (formerly known as Osmotica Pharmaceuticals plc), after serving as Executive Chairperson of one of its predecessor companies, Vertical/ Trigen Holdings, LLC. Previously, he held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, which he joined as Chief Operating Officer in March 2004, and was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Prior to joining King, Mr. Markison held various senior leadership positions at Bristol-Meyers Squibb, including President of Oncology, Virology and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity. Mr. Markison formerly served on the Board of Directors of Cosette Pharmaceuticals, Immunomedics, and Alere Inc. He is also a Director of the College of New Jersey. Mr. Markison holds a Bachelor of Science degree from Iona College.

Paul Blanchfield

President

Paul Blanchfield serves as President and oversees the Commercial, Manufacturing & Technical Operations, Medical and Quality functions. Mr. Blanchfield joined Lantheus in January 2020 as Chief Commercial Officer and was promoted to Chief Operating Officer in 2022 and to President in March 2023. Throughout his career in healthcare, he has held a variety of leadership roles in sales, marketing, strategy and operations. Prior to Lantheus, Mr. Blanchfield worked at Takeda Pharmaceutical Co. where he served as the Head of the U.S. Immunology Business Unit and managed a multi-billion-dollar P&L covering multiple rare diseases products. Prior to his time at Takeda, he served in several different roles at Shire Plc across almost six years, including as the Head of U.S. Immunology, General Manager of Nordic-Baltics, Head of Corporate Strategy and Chief of Staff to the CEO. In his time at Shire, Mr. Blanchfield launched multiple products, worked across nine different countries, oversaw a restructuring to increase commercial focus and reduce costs, and led efforts in M&A, corporate defense, integration and long-term corporate and portfolio strategy. Prior to his time at Shire, he worked at McKinsey & Company for five years, where he focused on healthcare, marketing and sales. Mr. Blanchfield earned an MBA / MA in education from Stanford University and an AB in economics from Duke University.

Jeff Humphrey, MD

Chief Medical Officer

Dr. Jeff Humphrey joined Lantheus as Chief Medical Officer in May 2024. Dr. Humphrey is a seasoned leader in drug development and a physician-scientist with more than 30 years of experience in clinical oncology, neuroscience, cancer research, and drug discovery, having led organizations developing drugs from pre-IND through launch. Dr. Humphrey spent more than two decades working for global pharmaceutical companies, including Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer, and subsequently held senior leadership positions at multiple clinical-stage biotechnology companies. Prior to joining Lantheus, he served as Chief Medical Officer of Constellation, Magenta, and Kyowa Kirin where he also served as Chief Development Officer and President of the US and EU research organizations. He is a co-author of over 60 peer-reviewed publications in molecular biology and clinical research. Dr. Humphrey earned a Doctorate in Medicine from Case Western Reserve University School of Medicine and an AB in Applied Mathematics from Harvard University. He is Board Certified in Oncology and Internal Medicine. He completed his medical residency at The Johns Hopkins Hospital and post-doctoral fellowships in human genetics and medical oncology at the US NIH and NCI.

Robert J. Marshall Jr.

Chief Financial Officer

Robert J. Marshall Jr. joined Lantheus as Chief Financial Officer and Treasurer in September 2018. Mr. Marshall brings to the Company more than 30 years of finance experience, including in M&A, capital markets and investor relations. Prior to joining Lantheus, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc., a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including Vice President, Investor Relations and Corporate Treasurer, and most recently as Vice President, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Bob was employed with Brown & Williamson Tobacco, a subsidiary of British American Tobacco, p.l.c., in Louisville, Kentucky, where he held several positions of increasing responsibility. Mr. Marshall holds a Master of Business Administration from Indiana University, South Bend, and a Bachelor of Business Administration in finance from the University of Notre Dame. Bob also holds the CFA designation.

Amanda Morgan

Chief Commercial Officer

Amanda Morgan joined Lantheus in November 2022 as Senior Vice President, Commercial, and was promoted to Chief Commercial Officer in March 2024. Ms. Morgan is an established commercial leader with significant experience launching multiple products across complex channels and markets. Throughout her career in healthcare, she has held a variety of leadership roles in commercial strategy, marketing, sales, and market access. Prior to Lantheus, Ms. Morgan worked at Acadia Pharmaceuticals and served as the Chief Revenue and Customer Officer where she led the commercial organization and served as a member of the executive committee. Prior to her time at Acadia, she served in a variety of roles at Baxter and Shire where she held Commercial executive positions of increasing responsibility. During her nine-year tenure at Shire, Ms. Morgan served as the U.S. Head of Sales responsible for a multi-billion-dollar franchise that was inclusive of hospital, outpatient, and healthcare professional settings of care. In addition, Ms. Morgan held the role of U.S. Head of Patient Marketing and Services and was responsible for the Immunology, Hematology, and Oncology franchises. Ms. Morgan earned a Bachelor of Business Administration degree from The University of Iowa.

Daniel Niedzwiecki

Chief Administrative Officer, General Counsel and Corporate Secretary

Daniel Niedzwiecki serves as Chief Administrative Officer, General Counsel and Corporate Secretary, and oversees the Legal, Compliance, Enterprise Risk Management, Human Resources, and Communications functions. Mr. Niedzwiecki brings over 20 years of broad and diverse legal and business experience in corporate, securities, capital markets, transactional, commercial and compliance matters. Dan joined Lantheus in 2013 and has served in positions of increasing responsibility since originally joining the Company as Assistant General Counsel and Assistant Corporate Secretary. Prior to joining Lantheus, Mr. Niedzwiecki was a private equity and mergers and acquisitions attorney with Weil, Gotshal & Manges and, prior to that, a securities and transactional attorney at Palmer & Dodge. Mr. Niedzwiecki started his legal career clerking for the Honorable Frank H. Freedman of the United States District Court for the District of Massachusetts. Mr. Niedzwiecki received a Juris Doctor from Boston University School of Law and a Bachelor of Arts in economics from Williams College.

Jean-Claude Provost, MD

Chief Science Officer

Jean-Claude Provost, MD, was appointed Chief Science Officer in May 2024. Dr. Provost previously held the role of Chief Medical Officer from April 2022 to May 2024. Dr. Provost brings to the Company more than 30 years of experience in international development of therapeutic drugs and diagnostic agents, including radiopharmaceuticals and contrast media agents and offers a wealth of scientific acumen, extensive research and development experience, and deep radiopharmaceutical and industry knowledge.

Dr. Provost joined Lantheus from his firm, Theranostics Consulting, where he provides research and development, medical and strategic consulting services to pharmaceutical and biotechnology companies and investment firms. In this capacity, he advised Lantheus for more than three years. Previously, he was head of global research and development for GE Healthcare’s pharmaceutical diagnostics division. Prior to his tenure at GE Healthcare, he co-founded Smo-Clinica, a contract research organization that specialized in clinical trial patient recruitment and management. He also held several management and clinical research positions with Pfizer, Bayer, Merck-Serono and Synarc-CCBR. Dr. Provost began his career as Research Physician in Clinical Pharmacology at St Antoine University Hospital (Sorbonne University, Paris). Dr. Provost holds degrees in Methodology and Statistics and Clinical Pharmacology from the University of Paris and a Doctorate in Medicine from Sorbonne University, Paris.

Jamie Spaeth

Chief People Officer

Jamie Spaeth joined Lantheus as Chief People Officer in July 2024. Ms. Spaeth is an established human resources leader with significant experience building teams and organizations, cultivating talent, fostering company culture and driving employee engagement through HR and business strategy. Prior to Lantheus, Ms. Spaeth worked at Corium, Inc. where she served as the Chief People Officer leading the company through significant growth and successful transformation from clinical to commercial-stage, including the launch of two innovative neuroscience products. Prior to her time at Corium, she served in a variety of roles at Sage Therapeutics and Shire where she held senior level HR positions of increasing responsibility. During her almost twelve-year tenure at Shire Plc, Ms. Spaeth held various roles across HR, eventually becoming the Head of HR for US Commercial. In 2018, Jamie was recognized by the Healthcare Business Women’s Association with a Rising Star award. Ms. Spaeth earned a Bachelor of Science degree in Hospitality and Tourism Management from the University of Massachusetts, Amherst, and a master’s degree in Human Resources from Suffolk University.

Other Key Leaders

Cheryl Ball

Senior Vice President, Strategy and Enterprise Planning

Cheryl Ball joined Lantheus in 2019 and serves as Senior Vice President, Strategy and Enterprise Planning. Ms. Ball brings more than 30 years of leadership, corporate strategic and portfolio planning, therapeutic area strategy, BD search and evaluation, and new product planning to the company. At Lantheus, she leads corporate and business development strategy, portfolio governance, and alliance management.

Prior to joining Lantheus, Ms. Ball led PPD’s Global Market Access Consulting Practice providing global market access, pricing and evidence generation strategy to pharmaceuticals companies in planning for new products in oncology, neuroscience and rare diseases. Prior to PPD, Ms. Ball was a leader in AstraZeneca’s New Opportunities segment, focused on identifying growth and BD opportunities outside of the established core business. Prior to AstraZeneca, Ms. Ball held leadership roles in life sciences strategy consultancies including Decision Resources Group and Quintiles (now IQVIA). She started her career in corporate finance and received a Bachelor of Science in Foreign Service with a concentration in International Finance and Commerce from Georgetown University.

Dorothy Barr

Senior Vice President, Manufacturing and Technical Operations

Dorothy (Dottie) Barr joined Lantheus in 2015 and has more than 25 years of experience leading all aspects of global supply chain and manufacturing operations, encompassing medical device, pharmaceutical and radio-pharmaceutical products. She currently serves as the Company’s Senior Vice President, Manufacturing and Technical Operations. Ms. Barr has served in positions of increasing responsibility at Lantheus, including most recently as Vice President of Manufacturing and Supply Chain. Prior to joining Lantheus, Ms. Barr was Vice President, Supply Chain, Materials and Logistics at T2 Biosystems. Prior to that, she held positions of increasing responsibility at Haemonetics, where she ultimately rose to the position of Vice President, Global Supply Chain. Ms. Barr earned a Bachelor of Arts in economics from Framingham State University and a Master of Business Administration from Babson College.

Kim Brown

Chief Accounting Officer

Kim Brown joined Lantheus in 2024 as the Chief Accounting Officer. Kim brings to Lantheus a strong background in accounting and finance with experience in an array of global environments, including life sciences. Most recently, Kim was the Vice President, Corporate Controller at Repligen Corporation, a publicly traded bioprocessing company focused on the development, manufacture and commercialization of innovative products used to manufacture biologic drugs. During her six years at Repligen, she served on the Finance team in roles of increasing responsibility. Prior to Repligen, Kim spent five years as Audit Manager at Grant Thornton LLP, the sixth largest accounting and advisory organizations in the U.S. Kim is a Certified Public Accountant (CPA) and is a member of the American Institute of CPAs. She earned a Bachelor of Science in Corporate Finance and Accounting, with a concentration in Health Industry, and a Master of Science in Accounting, both from Bentley University.

Lee Anne Howe

Chief Information Officer

Lee Anne Howe joined Lantheus in 2016 and is the Chief Information Officer. With over 20 years of experience as a results-driven IT leader in the life sciences sector, Ms. Howe is responsible for overseeing Lantheus’ information and technology strategy and the enterprise program management office. She is passionate about driving business transformation through innovative IT strategies and systems solutions.

Prior to joining Lantheus, Ms. Howe served as the Vice President, Information Technology Services at Bright Horizons Family Solutions. Prior to that, she was the Vice President, Global Information Systems at Boston Scientific, where she held various roles of increasing responsibilities across IT, Finance and International divisions. Ms. Howe began her career at General Electric in the Financial Management Training program and later worked in Belgium, implementing Shared Services in the Benelux region. Ms. Howe holds a Bachelor of Science degree from Penn State University.

Linda Lennox

Chief of Staff & Vice President, Corporate Communications

Linda Lennox joined Lantheus as Vice President, Corporate Communications and Chief of Staff in August 2020 with more than 25 years of leadership, communications and investor experience. At Lantheus, Ms. Lennox leads the development and execution of the internal and external global corporate communication strategy, including media and public relations, employee communications, and corporate social responsibility (CSR) functions, while ensuring that investor relations and patient advocacy efforts are aligned with the company vision, mission and goals.

Prior to joining Lantheus, Ms. Lennox served as Vice President, Investor Relations and Corporate Communications at AMAG Pharmaceuticals. Prior to joining AMAG, Ms. Lennox served as Senior Director, Investor Relations & Corporate Communications at Lantheus Medical Imaging, Inc. and prior to that as Vice President, Investor and Media Relations at Critical Therapeutics. Ms. Lennox spent 15 years in leadership, financial and communications positions of increasing responsibility at two separate publicly traded energy companies. Ms. Lennox started her career at Putnam Investments and Smith Barney, where she obtained her NASD Series 6, 7 and 63 licenses. She received a Bachelor of Arts in economics from the University of Vermont.

Joann Nestor

Senior Vice President, Legal Affairs

Joann Nestor joined Lantheus in July 2023 as Senior Vice President, Legal Affairs. Throughout her legal career, Ms. Nestor has counseled healthcare companies and has over 20 years of in-house legal experience in biotech and pharma. Prior to Lantheus, she was the global head of legal for Sanofi’s Specialty Care business. Ms. Nestor also held roles of increasing responsibility within the legal department at Genzyme Corporation, including as the sole attorney responsible for Genzyme’s FDA consent decree which was successfully vacated after 12 years. She began her legal career as a corporate associate at Ropes & Gray in Boston. Ms. Nestor has a Juris Doctor from Boston University School of Law and a Bachelor of Arts from Hamilton College.

Andrea Sabens

Vice President, Business Optimization

Andrea Sabens joined Lantheus in 2009 and brings more than 20 years of accounting and finance experience. She currently serves as the Company’s Vice President of Business Optimization. Ms. Sabens has served in positions of increasing responsibility at Lantheus, in which she has had leadership and oversight of the Controllership, FP&A, Tax, Treasury and shared services-related functions. Prior to joining Lantheus, Ms. Sabens held progressive financial management roles at Presstek, Inc. and Graphic Packaging International, Inc. Prior to that, she served as an Audit Senior for Ernst & Young. Ms. Sabens earned a Bachelor of Science in business administration from the University of New Hampshire and a Master of Business Administration, and Master of Science in organizational leadership from Southern New Hampshire University. She is a licensed Certified Public Accountant in the state of New Hampshire.

Carol Walker

Senior Vice President, Quality

Carol Walker has served as Senior Vice President, Quality since April 2018. She joined Lantheus in February 2015 as Vice President, Quality. Ms. Walker brings more than 30 years of industry experience in quality and medical technology, primarily in the medical device area. Prior to joining Lantheus, she served as Vice President of Quality Assurance and Regulatory Affairs for Intelligent Medical Devices, Inc. (IMDx), a company that designs, develops and manufactures in vitro diagnostic devices. Prior to that, Ms. Walker spent 11 years with Siemens Healthcare Diagnostics, where she held positions of increasing responsibility, including as Vice President of Quality Assurance. Earlier in her career, Ms. Walker held a variety of quality control positions during her 15-year tenure with Nova Biomedical, one of the 25 largest in vitro diagnostic companies in the world. Ms. Walker received a Bachelor of Science in medical technology from the Rochester Institute of Technology.

Our Board of Directors

Mary Anne Heino

Chairperson of the Board

Mary Anne Heino has served as a Director since August 2015, and became the Chairperson of our Board and a member of the Science and Technology Committee on March 1, 2024. She previously served as our Chief Executive Officer, a position she held from August 2015 until March 1, 2024, as our President and Chief Executive Officer, a position she held from August 2015 until March 2023, as our Chief Operating Officer, a position she held from March 2015 until August 2015, and as our Chief Commercial Officer, a position she held from April 2013 (when she joined the Company) until March 2015. Ms. Heino brings more than 30 years of diverse pharmaceutical industry experience to the Board. Prior to joining Lantheus, Ms. Heino held executive level roles at Angelini Labopharm LLC and Labopharm USA from February 2007 to March 2012. From May 2000 until February 2007, Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson (“J&J”) company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and held increasing roles in Sales and Marketing through 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor’s of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC. Member of the Science and Technology Committee

Brian Markison

Director

Minnie Baylor-Henry

Director

Minnie Baylor-Henry is a Director and a member of the Talent and Compensation Committee, the Science and Technology Committee, and the Nominating and Corporate Governance Committee. Ms. Baylor-Henry is the President of B-Henry & Associates, a consulting firm focused on providing regulatory and compliance strategy services to life sciences companies. Prior to assuming her current role, she was the Worldwide Vice-President for Regulatory Affairs for Johnson & Johnson’s Medical Devices & Diagnostics business, where she was directly responsible for coordinating the regulatory strategy for the approval of a wide portfolio of products globally. Prior to that, Ms. Baylor-Henry was a National Director for Regulatory & Capital Markets Consulting at Deloitte & Touche. From 1991–1999, she worked at the U.S. Food & Drug Administration (FDA), where she served in many roles, most notably as the FDA’s National Health Fraud Coordinator and, within the Center for Drugs, as the Director of the Division of Drug Marketing, Advertising and Communications. In addition, Ms. Baylor-Henry is a former President & Board Chair of the Drug Information Association and of the Food and Drug Law Institute. Ms. Baylor-Henry is currently an independent director of Apyx Medical, Paratek Pharmaceuticals and scPharmaceuticals. Ms. Baylor-Henry is also a member of the Board of Directors of several not-for-profit companies, including Mass Eye & Ear Hospital and Dress for Success Boston. Ms. Baylor-Henry received her pharmacy degree from Howard University’s College of Pharmacy and her law degree from Catholic University’s Columbus School of Law.

Member of the Talent and Compensation Committee Member of the Science and Technology Committee Member of the Nominating and Corporate Governance Committee

Gérard Ber, PhD

Director

Dr. Gérard Ber is a Director and a member of both the Talent and Compensation Committee and the Science and Technology Committee, serving on the Board of Directors since June 2020. Dr. Ber is also a member of the board of Y-mAbs Therapeutics, Inc. He served on the board of directors of Progenics Pharmaceuticals, Inc. until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG. He brings over 30 years of experience in molecular nuclear medicines, specifically including product development, production and commercialization of diagnostics and therapeutic products for several indications in various diseases. Member of the Talent and Compensation Committee Member of the Science and Technology Committee

Julie Eastland

Director

Julie Eastland is a Director and a member of the Audit Committee. Ms. Eastland served as the Chief Executive Officer of Harpoon Therapeutics, a publicly traded company, from November 2021, and a member of its Board of Directors from October 2018, until its acquisition by Merck Sharpe & Dohme in March of 2024. Ms. Eastland previously served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, a privately-held genetics medicine company focused on delivery of novel, anti-viral lipid nanoparticles therapeutics for respiratory diseases. Prior to ReCode, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics; a private biopharmaceutical company focused on targeting FGFR3 in bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, a publicly traded company acquired by Seattle Genetics in 2018. Prior to Cascadian, Ms. Eastland served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Ms. Eastland is currently an independent director and chair of the audit committee of Dynavax Technologies Corporation (NASDAQ: DVAX) and an independent director of Veana Therapeutics, a privately held company. Ms. Eastland received a Master of Business Administration from Edinburgh University Management School and a B.S. in finance from Colorado State University. Member of the Audit Committee

Samuel Leno

Director

Samuel Leno is a Director, the Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee, serving on the Board of Directors since May 2012. Mr. Leno is a strategic executive with more than 40 years of experience with complex multinational companies. He most recently held the positions of Executive Vice President and Chief Operations Officer at Boston Scientific. He previously served as Executive Vice President, Finance and Information Systems and Chief Financial Officer. He retired from Boston Scientific in December 2011. Prior to joining Boston Scientific, Mr. Leno served as Executive Vice President, Finance and Corporate Services and Chief Financial Officer at Zimmer Holdings, Inc. and Chief Financial Officer positions at Arrow Electronics, Inc., Corporate Express, Inc. and Coram Healthcare. Previously, he held a variety of senior financial positions at Baxter International, Inc. and American Hospital Supply Corporation. He is the Chairman of the Board of Directors and of the Audit Committee of Zest Anchors, Inc. He previously served on the Boards of Directors and the Audit Committees of Omnicare and TomoTherapy, Inc. and also served on the Board of Directors of Endotronix, Inc. Mr. Leno served as a Lieutenant in the United States Navy and is a Vietnam veteran. He holds a Bachelor of Science in accounting from Northern Illinois University and a Master of Business Administration from Roosevelt University. Chair of the Audit Committee Member of the Nominating and Corporate Governance Committee

Heinz Mäusli

Director

Heinz Mäusli is a Director and a member of the Audit Committee and the Nominating and Corporate Governance Committee, serving on the Board of Directors since June 2020. He is also a member of the board of Inventiva SA. He served on the board of directors of Progenics Pharmaceuticals, Inc. until its acquisition by the Company. Mr. Mäusli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., where he worked from 2003 to 2018 when the company was acquired by Novartis. Mr. Mäusli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently. He brings more than 15 years of experience in the molecular nuclear medicine industry, as well as significant management and executive experience. Member of the Audit Committee Member of the Nominating and Corporate Governance Committee

Julie McHugh

Director

Julie McHugh is a Director, the Chairperson of the Nominating and Corporate Governance Committee and a member of the Talent and Compensation Committee, serving on the Board of Directors since January 2017. Ms. McHugh brings over 30 years of experience in the pharmaceutical, biotech and medical devices industries. She recently served as Chief Operating Officer of Endo Health Solutions, Inc., where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to that, Ms. McHugh was CEO of Nora Therapeutics, Inc., a venture capital-backed biotech startup company focused on developing novel therapies for the treatment of infertility disorders. Previously, she served as Company Group Chairman for Johnson & Johnson’s worldwide virology business unit, and prior to that, she was President of Centocor, Inc., a J&J subsidiary. In this role, Ms. McHugh oversaw the development and launches of several products, including Remicade^® (infliximab), Prezista^® (darunavir) and Intelence^® (etravirine). Prior to joining Centocor, Ms. McHugh led the marketing communications for gastrointestinal drug Prilosec^® (omeprazole) at Astra-Merck Inc. Ms. McHugh currently serves on the Board of Directors of Evelo Biosciences, Inc., Ironwood Pharmaceuticals, Inc., and New Xellia Group A/S. She previously served on the Board of Directors of the Biotechnology Industry Organization, the New England Healthcare Institute, the Pennsylvania Biotechnology Association, Aerie Pharmaceuticals, Inc., EPIRUS Pharmaceuticals, Inc., Trevena Pharmaceuticals, Inc. and ViroPharma Inc. Ms. McHugh received a Master of Business Administration from St. Joseph’s University and a Bachelor of Science from Pennsylvania State University. Chair of the Nominating and Corporate Governance Committee Member of the Talent and Compensation Committee

Gary J. Pruden

Director

Gary J. Pruden is a Director, the Chairperson of the Talent and Compensation Committee and a member of the Audit Committee, serving on the Board of Directors since February 2018. Most recently, Mr. Pruden held a number of senior commercial leadership positions across both the medical device and pharmaceutical sectors of Johnson & Johnson (“J&J”) from 1985 until 2017. In April 2016, Mr. Pruden was appointed as a member of the Executive Committee of J&J, where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Prior to that, he held roles of increasing responsibility within J&J, serving as Worldwide Chairman in the Medical Devices division from 2015 to 2016, as Worldwide Chairman of Global Surgery Group from 2012 to 2015, as Company Group Chairman of Ethicon, Inc. from 2009 to 2012, as Worldwide President of Ethicon, Inc., a J&J subsidiary, from 2006 to 2009, and as President of the J&J subsidiary, Janssen-Ortho Inc. in Canada, from 2004 to 2006. Mr. Pruden has also served in several capacities, including Chairman of Technology & Regulatory Committee and Executive Committee Member with the Advanced Medical Technology Association, a medical device trade association. Mr. Pruden currently serves on the Board of Directors of Motus GI Holdings, Inc., Ossio, Inc. and Olympus Corporation. Mr. Pruden received his Bachelor of Science in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015. Chair of the Talent and Compensation Committee Member of the Audit Committee

James H. Thrall, MD

Director

Dr. James H. Thrall is a Director, the Chairperson of the Science and Technology Committee and a member of both the Nominating and Corporate Governance Committee and the Talent and Compensation Committee, serving on the Board of Directors since February 2018. Dr. Thrall currently holds the Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as Chairman of the Department of Radiology at the Massachusetts General Hospital from 1988 until 2013. Previously, Dr. Thrall served as Chairman of Radiology at the Henry Ford Hospital between 1983 and 1988, where he also served as a Physician Trustee and held the position of Vice Chairman of the Board of Governors of the Henry Ford Medical Staff. Dr. Thrall is a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies. Dr. Thrall received his M.D. from the University of Michigan in 1968 and trained in radiology and nuclear medicine at the Walter Reed Army Medical Center, Washington, D.C. Dr. Thrall returned to the University of Michigan in 1975 and was promoted to Professor in 1981. Chair of the Science and Technology Committee Member of the Nominating and Corporate Governance Committee Member of the Talent and Compensation Committee